Annual Meeting 2025 - DF Group faces new political challenges

• DF AG achieves profits for the fifth consecutive year
• Dividend payment of 0,06 € per share rejected
• Realign foreign trade financing now – strategic course set for the future

Cologne, 02 September 2025 – DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG) held its Annual General Meeting in Cologne last Friday. Around 60% of the share capital was represented. Numerous shareholders took the opportunity to hear directly from the Management Board about the past financial year and strategic plans for the future.

The Management Board first reported on the 2024/25 financial year, which was marked in particular by the acquisition of the assets of the insolvent Vagabund Brauerei GmbH – the company's first M&A deal. Despite the challenges associated with this, DF AG was able to report a positive annual result for the fifth time in a row.

In May 2025, another important milestone followed with the entry into the blood plasma market through the acquisition of a further asset deal, about which the Executive Board also provided shareholders with detailed information.

Surprisingly, the dividend proposal of €0.06 per share put forward by the Management Board and Supervisory Board was rejected by the majority shareholder. ‘The disappointment of many shareholders is understandable, especially since the Management Board and Supervisory Board had expressly supported the distribution,’ explained CEO Dr Behrooz Abdolvand. ‘The fact that the majority shareholder has now voted against a dividend was not foreseeable for anyone involved. We currently have no information about the reasons behind his decision.’

In his speech, Dr Abdolvand emphasised that the foreign trade finance business segment now needs to be realigned. The geopolitical environment had become even more challenging in recent weeks. This meant that the company needed to expand its geographical presence in the Middle East in a targeted manner in order to actively shape market developments – particularly in the strategic Food & Pharma sector – to its own advantage. At the same time, the company needed to become more independent by entering into new strategic alliances.

The shareholders approved all other items on the agenda by a large majority. The Executive Board and Supervisory Board were discharged, the Chairman of the Supervisory Board was reelected for another term of office, and the auditor was confirmed for the current financial year.

‘We were delighted to welcome significantly more shareholders here in Cologne this year than last year,’ said Dr Abdolvand. ‘With the new business areas in the brewery and blood plasma sectors, there was also significantly more to report. The numerous questions from our shareholders underscore the continuing high level of interest in our company. We hope that we have succeeded in communicating our vision of consistent diversification even more clearly at this meeting.’

As always, the detailed voting results can be found on our website at https://www.dfag.de/investor-relations/annual-general-meeting/

About DF Group

DF Group is a finance company with the business units Foreign Trade Finance, Proprietary Trading and M&A. The industry focus is on the food, beverages, pharmaceutical and healthcare sectors. As a specialist in foreign trade financing with a regional focus on the Middle East, Europe and Central Asia, we offer our clients customised product solutions - based on many years of experience, a strong network and comprehensive compliance expertise. M&A activities have also been an integral part of DF Group's business model since 2024.

Contact DF Deutsche Forfait AG

Guido Janzen
Director Investor Relations
Gustav-Heinemann-Ufer 56, 50968 Köln
T +49 221 97376-61

E investor.relations@dfag.de
www.dfag.de